Bipartisan Bill Aims To Deem Pharma Tactics Anti-Competitive
Two techniques that lawmakers say brand-name pharmaceutical companies use to keep out generics companies could become enshrined in federal law as anti-competitive business practices if Sens. Richard Blumenthal and John Cornyn...To view the full article, register now.
Already a subscriber? Click here to view full article